Australian biotherapeutics company CSL has reached an agreement with Chinese healthcare company Humanwell Healthcare Group to acquire an 80% equity stake in the latter’s subsidiary, Wuhan Zhong Yuan Rui De Biological Products (Ruide).
The acquisition is to be funded through CSL’s existing debt facilities and also includes milestone-based performance and payment mechanism to increase the stake further.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The purchase consideration for the acquisition is $352m.
Chinese pharmaceutical company Sunflower Pharmaceutical Group has acquired 10% stake in a pharmaceutical unit based in Xiangyang.
The purchase consideration for the acquisition involved approximately three million shares of the target company and totalled CNY40.33m ($5.94m).
Immunotech Laboratories, a drug development company based in the US, has been acquired by US-based oil and gas company, Eco-Petroleum Solutions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe stock transaction will result in an opportunity to bring a new immunotherapy to Europe and innovate HIV / AIDS treatments.
